Lilly’s $7 Billion Kelonia Deal Signals a New Phase for In Vivo Cell Therapy

Eli Lilly’s move to buy Kelonia for $7 billion is notable not just for its size, but for the kind of science it backs. In vivo CAR-T is a high-upside bet: if it works, it could avoid many of the manufacturing, turnaround-time, and cost constraints that have limited ex vivo cell therapies.

The strategic logic is clear. Big pharma has been searching for therapies that combine platform potential with clearer scalability, and cell engineering inside the patient could fit that brief. But the scientific and regulatory burden is equally high, because the technology must prove it can deliver precision without creating unacceptable off-target risks.

This deal also fits a broader pattern in life sciences: companies are no longer treating advanced modality deals as speculative side bets. Instead, they are assembling portfolios around next-generation platforms that may take years to mature but could command durable competitive advantage if they succeed.

For the market, the takeaway is that AI drug discovery is increasingly being paired with platform therapeutics rather than small, isolated programs. The industry is chasing not only faster discovery, but also new development models that can expand what a drug can be in the first place.